Average cost of drugs for extensively drug-resistant tuberculosis in Tunisia
Tunisia: Average cost of drugs for extensively drug-resistant tuberculosis was 40,560 constant 2022 US$ in 2023. ◆ Volatile
Average cost of drugs for extensively drug-resistant tuberculosis in Tunisia, 2017–2023
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of drugs for extensively drug-resistant tuberculosis in Tunisia is 40,560 constant 2022 US$, measured in 2023. That is the highest value across all 6 years on record.
Compared with earlier readings it is up 20.0% on the previous year and up 479.4% over ten years.
Tunisia ranks 1st of 56 countries on this measure, in the top 10%.
Average cost of drugs for extensively drug-resistant tuberculosis in Tunisia, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 7,000 constant 2022 US$ | — |
| 2018 | 7,000 constant 2022 US$ | +0.0% |
| 2020 | 3,600 constant 2022 US$ | -48.6% |
| 2021 | 3,800 constant 2022 US$ | +5.6% |
| 2022 | 33,800 constant 2022 US$ | +789.5% |
| 2023 | 40,560 constant 2022 US$ | +20.0% |
Tunisia compared with similar countries
- Tunisia's 40,560 constant 2022 US$ is above the median for lower middle income countries, which is 1,525 constant 2022 US$, 26.6× the median. (24 countries reporting)
- Tunisia's 40,560 constant 2022 US$ is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 2,000 constant 2022 US$, 20.3× the median. (7 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 7,000 constant 2022 US$ | 7,000 constant 2022 US$ | 7,000 constant 2022 US$ | 2 |
| 2020s | 20,440 constant 2022 US$ | 3,600 constant 2022 US$ | 40,560 constant 2022 US$ | 4 |
Countries ranked near Tunisia
More reference data data for Tunisia
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.148 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 1.86 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 3.38 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.1317 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 3.38 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 0.4961 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 0.1849 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 8.07 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 14.52 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 0.7169 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Tunisia?
- Average cost of drugs for extensively drug-resistant tuberculosis in Tunisia was 40,560 constant 2022 US$ in 2023, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Tunisia?
- The highest recorded value was 40,560 constant 2022 US$ in 2023.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Tunisia?
- The lowest recorded value was 3,600 constant 2022 US$ in 2020.
- How does Tunisia rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Tunisia ranks 1st out of 56 countries with data for 2023.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Tunisia?
- Over the last ten years it is up 479.4%. The long-run trend across the full record is volatile.
- Where does this Tunisia data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 6 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.